NCT05492682 2025-09-05START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of CancerValo Therapeutics OyPhase 1 Active not recruiting15 enrolled
NCT03132922 2024-01-22MAGE-A4ᶜ¹º³²T for Multi-TumorAdaptimmunePhase 1 Active not recruiting71 enrolled
NCT03399448 2023-06-22NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)University of PennsylvaniaPhase 1 Terminated3 enrolled